Trump Pushes Global Trade War Back to the Top of His Agenda
White House press secretary Karoline Leavitt said Trump would sign an executive order extending the date when his so-called reciprocal tariffs would take effect, previously scheduled to expire at 12:01 a.m. Wednesday. Additionally, Trump sent letters to a handful of nations outlining tariff rates they would pay if they didn't strike trade deals with the U.S. by Aug. 1
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 11 best debt-free stocks to invest in right now. On July 2, Morgan Stanley analyst Sean Laaman initiated coverage on BioMarin with a Buy rating and a $97 price target, citing a favorable outlook despite ongoing competitive concerns. Laaman's optimism centers on Voxzogo, BioMarin's therapy for achondroplasia, a rare disorder affecting bone growth. While Ascendis Pharma's TransCon CNP could pose competition due to its longer half-life, Laaman notes that it still faces key challenges, including ongoing patent litigation. Importantly, he believes investors may be underestimating Voxzogo's broader potential, particularly in other indications such as hypochondroplasia. A close up photograph of a vial of a new biotechnological drug candidate in development. The analyst also pointed to the CANOPY clinical program, which is evaluating Voxzogo in conditions linked to SHOX gene mutations, as a promising path for further label expansion. In Laaman's view, this pipeline optionality is not fully reflected in BioMarin's current valuation. Trading near a 10-year low, the stock appears to already account for most of the perceived risks. Given the strength of Voxzogo's current performance, expansion potential, and an underappreciated pipeline, Laaman sees a compelling upside case for BioMarin shares from current levels. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for rare diseases and medical conditions worldwide. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Wells Fargo Downgrades KLA Corporation (KLAC) Stock to Equal Weight
KLA Corporation (NASDAQ:KLAC) is one of the Top 10 Software and Technology Stocks to Buy Now. Wells Fargo downgraded the company's stock to 'Equal Weight' from 'Overweight' with a price objective of $920, up from the prior target of $870, as reported by The Fly. As per the firm, the company's shares have significantly outperformed the group and trade well above the median price to earnings at ~26x. Wells Fargo anticipates KLA Corporation (NASDAQ:KLAC) to outperform the wafer fab equipment (WFE) market overall. However, it questioned the ability to provide further upside. The inner workings of a semiconductor manufacturing facility, neon hued machines humming with activity. KLA Corporation (NASDAQ:KLAC) demonstrated optimism about its growing relevancy in semiconductor manufacturing. The leadership in process control remains a critical enabler of leading-edge AI investments by its customers. In Q3 2025, the company saw total revenues of $3.06 billion. It saw GAAP diluted EPS of $8.16 and non-GAAP diluted EPS of $8.41. Both of these were above the midpoints of their respective guidance ranges. Parnassus Investments, an investment management company, released the Q4 2024 investor letter. Here is what the fund said: 'We also added several new positions, including two in Information Technology: Workday, a category leader for enterprise cloud applications for finance and human resources, and KLA Corporation (NASDAQ:KLAC), a leader in semiconductor process control. KLA, a leader in semiconductor process control, benefits from inherently high switching costs, structurally higher demand for advanced semiconductors and increasingly complex semiconductor manufacturing. The company has a strong management team that is positioning it well for long-term growth. Concerns about weaker demand in China have impacted KLA's stock price recently, but we believe the secular growth in other regions could offset the risk in the longer term.' While we acknowledge the potential of KLAC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
14 minutes ago
- Yahoo
Stifel Stands by Okta (OKTA) with $130 Target as Identity Demand Grows
Okta Inc. (NASDAQ:OKTA) is one of the 11 best debt-free stocks to invest in right now. Stifel Nicolaus analyst Adam Borg maintained his Buy rating on Okta in a June 25 note, holding the price target steady at $130. While recent sentiment around the stock has been mixed, Borg believes the company's long-term positioning remains solid, particularly as demand for identity-focused cybersecurity solutions continues to rise. A user in a cafe using a laptop to access the secure identity platform with a single sign-on. Okta's dual focus on Workforce Identity and Customer Identity is gaining traction, with early signs of success from newer products pointing to stronger adoption across both segments. Borg noted that recent improvements in go-to-market execution are also helping drive better results, potentially setting the stage for a revenue and RPO (Remaining Performance Obligations) reacceleration. He believes that if this momentum continues, it could translate into meaningful improvements in operating margins and stronger free cash flow over time. From a valuation standpoint, Borg believes that while the broader market remains divided on the stock, the valuation is reasonable relative to the company's upside potential. All these factors support his optimistic view. Okta Inc. (NASDAQ:OKTA) offers a suite of products and services used to manage and secure identities, enabling users to access applications in the cloud or on-premises from various devices. While we acknowledge the potential of OKTA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
